Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals' board, at its May 15, 2025 meeting, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion from Pankaj R. Shah & Associates. On a consolidated basis, FY25 total income nearly doubled to Rs 417.51 Cr from Rs 217.34 Cr in FY24, while profit after tax grew about 78% to Rs 58.34 Cr (vs Rs 32.71 Cr), and diluted EPS rose to Rs 16.12 from Rs 12.21. Q4 FY25 was relatively flat year-on-year with profit after tax of Rs 17.97 Cr (vs Rs 16.43 Cr). Total consolidated assets surged to Rs 1,226.86 Cr from Rs 621.88 Cr, largely on the back of the December 2024 IPO. The board also appointed M/s. Mukesh H. Shah & Co. as secretarial auditor for five years (FY26–FY30, pending shareholder approval), approved changes in senior management (Anish Makwani appointed; Malay Patel resigned), and amended the UPSI fair disclosure code.
Strong FY25 show with revenue and profit nearly doubling signals healthy post-IPO growth, though Q4 was muted and Rs 343.25 Cr of IPO proceeds remain unutilized (parked in FDs) which may draw investor attention. Routine governance items (auditor and SMP changes) are unlikely to move the stock on their own.